144 related articles for article (PubMed ID: 37457220)
61. Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series.
Bertolini F; Zunarelli E; Baraldi C; Valentini A; Del Giovane C; Depenni R; Falasca A; Giacobazzi P; Malagoli M; Meletti S; Fontana A; Conte P;
Tumori; 2012 Nov; 98(6):756-61. PubMed ID: 23389363
[TBL] [Abstract][Full Text] [Related]
62. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
63. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Toms SA; Kim CY; Nicholas G; Ram Z
J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
[TBL] [Abstract][Full Text] [Related]
64. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
65. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.
Ward ZJ; Scott AM; Hricak H; Atun R
Lancet Oncol; 2021 Mar; 22(3):341-350. PubMed ID: 33662286
[TBL] [Abstract][Full Text] [Related]
66. Refined efficacy and outcome estimates of surgical treatment in oldest-old patients with glioblastomas based on competing risk model and conditional survival analysis: A surveillance, epidemiology, and end results population-based study.
Zhao L; Gong K
Clin Neurol Neurosurg; 2022 Oct; 221():107391. PubMed ID: 35930955
[TBL] [Abstract][Full Text] [Related]
67. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.
Rhome R; Fisher R; Hormigo A; Parikh RR
J Neurooncol; 2016 Jun; 128(2):241-50. PubMed ID: 26970981
[TBL] [Abstract][Full Text] [Related]
68. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
[TBL] [Abstract][Full Text] [Related]
69. The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma.
Lopez Ramos C; Brandel MG; Steinberg JA; Wali AR; Rennert RC; Santiago-Dieppa DR; Sarkar RR; Pannell JS; Murphy JD; Khalessi AA
J Neurooncol; 2019 Jan; 141(1):159-166. PubMed ID: 30460629
[TBL] [Abstract][Full Text] [Related]
70. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
[TBL] [Abstract][Full Text] [Related]
71. The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2021 Apr; 21(1):387. PubMed ID: 33836694
[TBL] [Abstract][Full Text] [Related]
72. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma.
Liu EK; Yu S; Sulman EP; Kurz SC
J Neurooncol; 2020 Aug; 149(1):55-64. PubMed ID: 32617722
[TBL] [Abstract][Full Text] [Related]
73. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience.
Matsui JK; Allen PK; Perlow HK; Johnson JM; Paulino AC; McAleer MF; Fouladi M; Grosshans DR; Ghia AJ; Li J; Zaky WT; Chintagumpala MM; Palmer JD; McGovern SL
J Neurooncol; 2023 Jul; 163(3):717-726. PubMed ID: 37440097
[TBL] [Abstract][Full Text] [Related]
74. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
[TBL] [Abstract][Full Text] [Related]
75. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
76. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
77. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
[TBL] [Abstract][Full Text] [Related]
78. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
79. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
[TBL] [Abstract][Full Text] [Related]
80. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
